Allergen Subcutaneous Immunotherapy (SCIT) and Allergy Immunotherapy (AIT) Coverage Criteria
Customize your policy alerts
Sign up for all Medicare policy alerts
Know when Medicare releases new policies or updates existing guidance.
Monitor payer policy activity
Medicare medical policy governing coverage and medical necessity criteria for allergen immunotherapy (including SCIT and venom immunotherapy) for Medicare members served by Providence-affiliated plans; includes guidance on home administration, provider requirements, and use of Novitas LCD criteria when Medicare criteria are not fully established.
New Medicare Advantage medical policy
Coverage and Medical Necessity Criteria
Medical necessity criteria for AIT/SCIT
Covered when ALL of the following conditions are met or appropriately considered per adopted LCD guidance and Company criteria
See adopted Novitas LCD and Company rationale.
Presence of specific IgE alone without clinical correlation does not indicate therapy.
Antigen preparation by non-physician providers is considered not medically necessary and may be denied.
Frequent or routine home immunotherapy is not appropriate under any circumstances.
Indications for Allergen Immunotherapy (general)
Covered when ALL of the following are met:
Decision to begin immunotherapy should consider patient preference, adherence, symptom severity and duration, and prior therapies.
Venom Immunotherapy (VIT)
Covered when ALL of the following are met:
Fire ant venom extract is not available; whole-body extract may be used for diagnostic testing and immunotherapy for fire ant allergy.
Administration and Monitoring Requirements
Covered when ALL of the following are met:
Home administration is allowed only in rare, exceptional cases with informed consent and a trained administrator; accelerated (rush/cluster) schedules carry higher systemic reaction risk and require careful consideration.
General coverage conditions
Covered when ALL of the following are met
Documentation and coding rules including MUEs apply; presence of FDA 510(k) does not by itself establish medical necessity.
Services that are explicit exclusions under Medicare or the member's Evidence of Coverage (EOC) are not covered. This includes services that are cosmetic or otherwise not medically reasonable and necessary under Title XVIII of the Social Security Act, §1862(a)(1)(A). In addition, antigen preparation must be performed by an MD or DO; antigen preparation performed by non-physician providers (for example, nurse practitioners) is considered not medically necessary and may be denied.
Certain methods of immunotherapy are not supported by the available literature and therefore are not covered. Specifically, oral and sublingual immunotherapy for food hypersensitivity, neutralization-provocation therapy, the low-dose Rinkel method, intranasal, intrabronchial, intralymphatic, and epicutaneous approaches are not supported by the evidence and are excluded from coverage.
The quality of evidence does not support immunotherapy for several conditions; therefore these uses are not recommended or covered. Notably, food hypersensitivity, cockroach hypersensitivity, and chronic urticaria and/or angioedema lack sufficient evidence to justify allergen immunotherapy and are excluded from coverage. Use of unsupported formulations (e.g., allergoids and adjuvants) is also not supported.
Medicare-assigned coding guidance affects certain complete service codes. CPT codes 95120–95134 have been assigned a Medicare Status Indicator of 'I' (Not valid for Medicare purposes). While these codes represent complete service reporting (preparation/provision plus injection), they are not valid for Original Medicare; Medicare Advantage plans may accept them depending on plan policy. In addition, CPT 95134 (reporting five stinging insect venoms) is specifically noted as not allowed by Medicare.
Routine or frequent home administration of allergen immunotherapy is considered not medically necessary and is generally inappropriate. Home administration may be considered only in rare, exceptional circumstances when documentation demonstrates that the benefit clearly outweighs the risks (for example, a patient with venom‑induced anaphylaxis in a remote location) and the individual administering injections is trained and equipped to recognize and manage anaphylaxis with informed consent documented. Use of home SCIT as a routine office practice is not medically necessary.
Home administration of allergen immunotherapy should be limited to exceptional cases and is not medically necessary when the criteria for rare exceptions are not met. Frequent or routine home immunotherapy is explicitly considered inappropriate, and informed consent plus evidence of a trained administrator are required for any approved home administration.
Unlisted procedure codes submitted for services that this policy identifies as not covered will be denied as not covered. When an unlisted code is submitted for a potentially covered service under this policy, prior authorization is recommended to avoid post‑service denial; all unlisted codes are reviewed for medical necessity, correct coding, and pricing at the claim level.
Billing, CPT Codes, and Coding Guidance
| 95120-95134 | Complete service codes including provision/preparation and injection; CMS-assigned Status 'I' (not valid for Medicare purposes) |
| 95144-95170 | Antigen and preparation only — supervision of preparation and provision of antigens (various specific codes and dose specifications) |
| 95165 | Supervision of preparation and provision of antigens; single or multiple antigens (specify number of doses) |
| 95170 | Supervision of preparation and provision of antigens; whole body extract of biting insect or other arthropod (specify number of doses) |
Provider Requirements, Documentation, and Operational Guidance
Supervision and observation requirements
Immunotherapy must be administered under direct supervision in a clinical setting capable of recognizing and managing anaphylaxis. Patients should be observed for at least 30 minutes following injections (longer when clinically indicated). Administration may occur in the prescribing physician's office or another health-care facility only if the physician and staff are trained and equipped to recognize and treat anaphylaxis. Routine or frequent home administration is not appropriate except in rare, individualized circumstances where benefits clearly outweigh risks and appropriate informed consent has been obtained.
- Observe patient ≥30 minutes after injection unless documentation supports a different interval
- Administration location must have equipment/medications/personnel to treat anaphylaxis
- Home administration only in exceptional cases with individualized risk/benefit assessment and informed consent
Denial triggers
Services where antigen preparation is not performed by a physician (MD/DO) are considered not medically necessary and may be denied. Ensure antigen preparation and oversight comply with Medicare requirements (Medicare Benefit Policy Manual, Chapter 15, §50.4.4.1 and applicable LCDs).
- Antigen preparation must be performed by an MD or DO; services prepared by non-physician providers (e.g., nurse practitioner) may be denied
- Follow Medicare Benefit Policy Manual and applicable LCDs (e.g., L40050, L36240) for physician preparation requirements
Clinical risk exclusions
Initiation of immunotherapy is not appropriate for patients with clinical risks that substantially increase the likelihood of severe reactions. Prior to initiation, assess comorbidities, current medications, and ability to cooperate with therapy.
- Severe or uncontrolled asthma is an exclusion for initiating immunotherapy
- Significant cardiovascular disease or other comorbid conditions that increase risk may preclude initiation
- Patients on beta-blockers and/or ACE inhibitors require individualized risk/benefit assessment before inhalant or venom immunotherapy
- Home administration is inappropriate for most patients and should be reserved only for rare exceptional circumstances
Bundling and unlisted code denials
Component services reported with comprehensive service codes will be denied as bundled. Use either complete service codes (95120-95134) OR a combination of injection (95115, 95117) and antigen (95144-95170) codes — not both for the same service. If no specific code exists, an unlisted code may be used but is subject to review; prior authorization is recommended for unlisted codes related to potentially covered services to avoid post‑service denial.
- Do not report 95115-95117 or 95144-95170 together with 95120-95134 for the same service — these will deny as bundled
- Unlisted codes are reviewed at claim level for necessity, coding, and pricing; unlisted codes for non-covered services will be denied
- Prior authorization is recommended when billing unlisted codes for potentially covered services
Required documentation for review
Medical necessity review requires complete documentation per the Novitas LCA A56538 and adherence to publicly accessible Medicare guidance when applicable. Documentation must support the clinical indication, testing, treatment plan, and unit justification.
- Follow Novitas local coverage article (LCA) A56538 for billing and documentation guidance
- Provide clinical history correlating positive IgE/skin test results with patient symptoms and exposure
- Document assessments of risk (e.g., asthma control, cardiovascular disease, medications such as beta‑blockers/ACE inhibitors)
Prescription and administration documentation
Prescriptions for immunotherapy must clearly document dosing and scheduling details and be retained in the medical record. The prescribing provider should be trained and experienced in immunotherapy.
- Prescription must state initial dose, target maintenance dose, and immunotherapy schedule
- Must specify chosen allergen extracts and rationale based on medical and exposure history and specific IgE testing
- Prescribing provider should be trained and experienced in prescribing and administering immunotherapy
Documentation and unit justification
All claimed units must be justified in the medical record, coded correctly, and reported on the preparation date. Do not split units across multiple dates or claims. Documentation must support the number of vials/preparations and all ancillary services billed.
- Units should be billed on the preparation date and not split over subsequent days
- Date of service on the claim must match the actual date services were rendered
- Medical record must justify all units, services rendered, and coding (including services supporting vial preparation, administration, and observation)
Clinical sequencing considerations
Clinical decision to begin immunotherapy should incorporate guideline-based sequencing: confirm correlation of positive testing with clinical history, assess symptom severity/duration, and consider alternative treatments before initiating immunotherapy.
- Begin immunotherapy when positive specific IgE/skin testing aligns with history and triggers and when symptoms persist despite avoidance and pharmacotherapy
- Consider patient preference, adherence likelihood, medication requirements, and adverse effects when deciding to initiate immunotherapy
- Perform detailed clinical history, physical exam, and appropriate laboratory testing prior to initiation
Consideration of prior therapies
Prior to prescribing immunotherapy, providers should document trials of and responses to prior therapies and rationale for proceeding to immunotherapy.
- Document trials of pharmacotherapy (e.g., intranasal corticosteroids, antihistamines), environmental control/avoidance measures, and the response to these therapies
- Record symptom severity and duration and patient preference influencing decision to start immunotherapy
Utilization expectations
Allergen immunotherapy should be provided at frequencies supported by current medical literature and standards of practice. Billing must reflect medically reasonable and necessary frequency and unit counts; claims are subject to NCCI and MUE edits.
- Perform services at frequencies indicated by guidelines and literature; justify frequency in the medical record
- All units reported must be supported and coded correctly; claims may be audited for utilization
- Policy does not override NCCI procedure-to-procedure bundling edits or CMS MUEs — consult CMS resources for coding guidance
Background and Rationale
Allergen immunotherapy (AIT) refers to the repeated administration of specific allergens to individuals with IgE‑mediated conditions to provide protection against allergic symptoms and inflammatory reactions associated with natural exposure to those allergens. AIT is effective for aeroallergens (pollen, animal dander, dust mite, mold) and for Hymenoptera (stinging insect) venom hypersensitivity, and it may prevent progression to asthma in some patients. Patient selection should be based on a clinical history consistent with IgE‑mediated disease and concordant positive specific IgE or skin testing; therapy is intended for patients whose symptoms are not adequately controlled by avoidance measures and pharmacotherapy or who wish to reduce long‑term medication use.
Definitions and Key Terms
Policy Changes and Revision History
New Medicare Advantage medical policy for allergen subcutaneous immunotherapy (SCIT) and allergy immunotherapy (AIT) was established and became effective.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.